Navigation Links
Study Would Pave Way for the Development of New Drugs That Targets TB Proteasome

A new study was conducted to understand the biochemistry and structure of a protein-cleaving complex (proteasome) that is essential to the TB bacterium’s survival. The findings were published in the journal Molecular Microbiology. // The study’s main aim was to design effective treatment for the disease tuberculosis (TB). The study was done by scientists from the U.S. Department of Energy’s Brookhaven National Laboratory and collaborating institutions. Biophysicist Huilin Li, who led Brookhaven’s role in the research, said that the study also plans to analyze the difference present in the structure and biochemistry of the TB bacterial proteasome from those found in human cells. This would greatly improve prospects for developing specific proteasome-based anti-tuberculosis treatments.

Mycobacterium tuberculosis is the bacterium that causes TB in man. Statistics show that one out of three people is infected with the disease. Largely the infected person is not aware of the presence of the disease as it does not manifest any observable symptoms. This is due to the fact that the bacteria is kept in check within immune system cells known as macrophages by compounds such as nitric oxide that kills or disables most of the bacteria. Inside the macrophage the immune cells damages and destroys the bacterial proteins. These accumulated proteins have to be removed otherwise it will in turn destroy the cell.

But the TB bacteria remove the damaged proteins with the help of a protein-cleaving complex known as a proteasome. It is highly specific for degrading protein parts. This protein allows Mycobacterium tuberculosis to remain in macrophages, and possibly go on to cause active TB infections. Hence Li said this protein should be made as a major target for the production of new anti-TB drugs. By this technique TB microbes can be eradicated from infected individuals who show no signs of infection. But the major drawback is that human cells also contain proteaso mes for degrading unneeded proteins. This process is essential for human cell survival. So any drug targeting the TB proteasome would have to be extremely specific. Hence studies should be very specific in identifying the unique characteristics that would allow such a targeted drug design.

The studies reveal highly specific details of the proteasome active site and mechanism, which will be invaluable to designing TB specific inhibitors. The proteasome structure was revealed by Guiqing Hu and collaborators using cryo electron microscopy in Brookhaven Lab’s Biology Department and by x-ray crystallography at the Lab’s National Synchrotron Light Source. The biochemical studies were conducted at Weill Medical College of Cornell University by Gang Lin in a group led by Carl Nathan. Other collaborating institutions included the Max Planck Institute of Biochemistry, Cold Spring Harbor Laboratory, and Millennium Pharmaceuticals. This research was funded by the Office of Biological and Environmental Research within the U.S. Department of Energy’s Office of Science, the National Institutes of Health, and Brookhaven’s Laboratory Directed Research and Development program.

'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/20/2017)... ... February 20, 2017 , ... Best ... an employee health benefit for companies that want to help members of their ... employees will have access to Watson’s suite of oncology offerings for insights on ...
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and Center for ... joint event at Chuck E. Cheese’s locations throughout New England, New York and New ... opportunity to experience the fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. ...
(Date:2/19/2017)... ... February 19, 2017 , ... Braun Industries will be ... & Exposition, the event will take place February 23-25, 2017 at the Calvin L. ... in Booth #909 with three new ambulances on display. , “JEMS ...
(Date:2/18/2017)... VA (PRWEB) , ... February ... ... of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends in ...
(Date:2/18/2017)... , ... February 17, 2017 , ... Park Cities Pet ... Behave” Show on the Pet Life Radio network. The episode, which was posted ... of topics including: what factors led to Park Cities Pet Sitter’s being awarded the ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)...   Risperdal lawsuits involving gynecomastia (male breast growth) ... of the atypical antipsychotic medication continue to move forward ... Common Pleas, where the state,s Risperdal docket has been ... notice posted on the Court,s website , the ... 9, 2017 at 11:00 a.m. (In Re: Risperdal Litigation, ...
(Date:2/17/2017)... LOUIS , Feb. 17, 2017   FormFast ... has announced a new partnership with Engage , ... the United States . FormFast will serve as ... of Engage,s implementations with MEDITECH .  ... provides essential functionality to complement and enhance the electronic ...
(Date:2/17/2017)... , Feb. 17, 2017  BioDigital, Inc., ... the partnership of their 3D body mapping technology ... IT.  The new integration will be used to ... interactive model of the human body. BioDigital pilots ... clinicians time, while also increasing the precision of ...
Breaking Medicine Technology: